Find 3-2,4-Dimethoxybenzylidene-Anabaseine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 156223-05-1, Gts 21 dihydrochloride, Dmxba, Gts-21 (dihydrochloride), Dmxb-anabaseine, 3-[(5e)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2h-pyridin-6-yl]pyridine;dihydrochloride
Molecular Formula
C19H22Cl2N2O2
Molecular Weight
381.3  g/mol
InChI Key
BXKYFUGAAFLYJL-BXGYHSFXSA-N

3-2,4-Dimethoxybenzylidene-Anabaseine
1 2D Structure

3-2,4-Dimethoxybenzylidene-Anabaseine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine;dihydrochloride
2.1.2 InChI
InChI=1S/C19H20N2O2.2ClH/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16;;/h3,6-9,11-13H,4-5,10H2,1-2H3;2*1H/b15-11+;;
2.1.3 InChI Key
BXKYFUGAAFLYJL-BXGYHSFXSA-N
2.1.4 Canonical SMILES
COC1=CC(=C(C=C1)C=C2CCCN=C2C3=CN=CC=C3)OC.Cl.Cl
2.1.5 Isomeric SMILES
COC1=CC(=C(C=C1)/C=C/2\CCCN=C2C3=CN=CC=C3)OC.Cl.Cl
2.2 Synonyms
2.2.1 MeSH Synonyms

1. 3-(2,4-dimethoxybenzylidene)anabaseine

2. Dmxba

3. Gts 21

4. Gts-21

2.2.2 Depositor-Supplied Synonyms

1. 156223-05-1

2. Gts 21 Dihydrochloride

3. Dmxba

4. Gts-21 (dihydrochloride)

5. Dmxb-anabaseine

6. 3-[(5e)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2h-pyridin-6-yl]pyridine;dihydrochloride

7. Dmbx-a

8. Dmbx-anabaseine

9. (e)-3-(2,4-dimethoxybenzylidene)-3,4,5,6-tetrahydro-2,3'-bipyridine Dihydrochloride

10. 3-(2,4-dimethoxybenzylidene)-3,4,5,6-tetrahydro-2,3'-bipyridine Dihydrochloride

11. 156743-66-7

12. Gts-21 2hcl

13. Gts 21

14. Dmxb

15. Schembl2561893

16. Schembl12274790

17. Ex-a5724

18. Hy-14564a

19. Akos037515500

20. Cs-5486

21. (e)-3-((2,4-dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-2,3'-bipyridine Dihydrochloride

22. 2,3'-bipyridine, 3-((2,4-dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-, Dihydrochloride, (e)-

23. Ac-31954

24. Gts-21, >=97% (hplc)

25. 3-(2,4-dimethoxybenzylidene)anabaseine Dihydrochloride

26. 3-(2,4-dimethoxybenzylidene)-anabaseine Dihydrochloride

27. 3-(3-(2,4-dimethoxybenzyl)-3,4,5,6-tetrahydropyridin-2-yl)pyridine Dihydrochloride

28. (e)-3-(3-(2,4-dimethoxybenzylidene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine Dihydrochloride

2.3 Create Date
2006-04-28
3 Chemical and Physical Properties
Molecular Weight 381.3 g/mol
Molecular Formula C19H22Cl2N2O2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count4
Exact Mass380.1058333 g/mol
Monoisotopic Mass380.1058333 g/mol
Topological Polar Surface Area43.7 Ų
Heavy Atom Count25
Formal Charge0
Complexity447
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Nicotinic Agonists

Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (See all compounds classified as Nicotinic Agonists.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty